Ascorbyl palmitateAscorbyl palmitate
MedChemExpress (MCE)
HY-B0987
137-66-6
L-Ascorbic acid 6-hexadecanoate
6-O-Palmitoyl-L-ascorbic acid
99.61%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Room temperature in continental US
may vary elsewhere.
Ascorbyl palmitate is an orally active ester formed from ascorbic acid and palmitic acid, used as an antioxidant and food additive. Ascorbyl palmitate in preventing fat and oil oxidation is more efficient than Butylated hydroxyanisole (HY-B1066) and Butylated hydroxytoluene (HY-Y0172). Ascorbyl palmitate mitigates inhibition of collagen synthesis by select calcium and sodium channel blockers. Ascorbyl palmitate induces Apoptosis in human umbilical vein endothelial cells (HUVECs). Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome.
Ascorbyl palmitate (25-400 μM, 24 h and 48 h) induces cell cytotoxicity and inhibits cell growth in HUVECs in a dose- and time-dependent manner[1]. Ascorbyl palmitate (125 μM, 24 h and 48 h) inhibits proliferation of HUVECs and induces cell death by inducing apoptosis, which decreases Bcl-2 gene expression ratio and increases Caspase-3, 9 activities in HUVECs[1]. Ascorbyl palmitate (1.25-20 μM, 72 h) dependent extracellular matrix (ECM) deposition of collagen type l is significantly reduced in aortic smooth muscle cells, which is inhibited by Nifedipine (HY-B0284) (50 µM, 72 h)[2]. Ascorbyl palmitate (0-20 μM, 1 h) has stronger inhibitory activity against NLRP3 inflammasome through its antioxidant ability than ascorbic acid in LPS (HY-D1056)-primed bone marrow-derived macrophages (BMDMs)[3].
Ascorbyl palmitate (25 mg/kg, i.p., every 2 days for 10 or 14 days) alleviates LPS (HY-D1056)-induced NLRP3 inflammasome activation, dextran sulfate sodium (DSS) (HY-116282C)-induced colitis and experimental autoimmune encephalomyelitis (EAE) in mice[3].
| | | |
| | | | | |
[1]. Sohrabi Y, et al. Cytotoxicity and Genotoxicity Assessment of Ascorbyl Palmitate (AP) Food Additive[J]. Adv Pharm Bull. 2018 Jun
8(2):341-346. [Content Brief]
[2]. Ivanov V, et al. Inhibition of collagen synthesis by select calcium and sodium channel blockers can be mitigated by ascorbic acid and ascorbyl palmitate. Am J Cardiovasc Dis. 2016 May 18
6(2):26-35. [Content Brief]
[3]. Zhang L, et al. Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome[J]. Int Immunopharmacol. 2024 Apr 20
131:111915. [Content Brief]
[4]. Jonker D, et al. Comparison of the effects of ascorbyl palmitate and L-ascorbic acid on paracetamol-induced hepatotoxicity in the mouse[J]. Toxicology. 1988 Nov 30
52(3):287-95. [Content Brief]